English Translation

Contrast Media K²¿TÇ±ç« èhèV²³iç

Behind every image is a patient. dÆèY²èT± Q²èf³f ódQ²öc GK²èT± ô³fçMé ZçöK²
We provide a comprehensive portfolio of contrast ô³fçMé I Y²çöa³f dÆèoèV²³iô³f Q²èf³f RcÅ Açh³fç ècö³i
media to help meet patient and procedural needs GöoèQ² K²¿TÇ±ç« èhèV²³iç³f èfå½ïY² o¡ç³f
across imaging modalities.
Products dÆV²çr²
Focusing on precision medicine from injection to BcöRÊmc óZöK² ô³fçM ècbáç³fc, ècgëá²k Inëób³f Id³f cR³f|
diagnosis. Each dose, each patient, improving every dÆèY²èT± ôV²çR, dÆèY²èT± ô³fçMé, dÆèY²èac DšèY²|
Açhçöa³f K²¿TÇ±ç« èhèV²³iç dÆV²çr² Gfü ohçbçöc³f èfå½ïY²
day. Explore our
o¡ç³f ôaLëc
broad portfolio of contrast media products and
solutions.
X-ray Gu-ô³f
CT èoèT±
MRI GhAç³fAçB
110m+ 110 èhèk³ic+
doses currently ôV²çR oç³fç èföm GK² fQ²ö³f D×dçèaY² p³i
produced globally
every year1
30m 30 èhèk³ic
more iodinated contrast Açö³içèV²c i늺 K²¿T±ç« èhèV²³iç ôV²çR 2025 G³f hõbÅ
o³ff³fçp K²³fç pöf
media doses to be delivered
annually by 20251
4 cGMP 4 èoèRGhèd
accredited contrast oÂéKï²Y² oç³fç èföm K²¿TÇ±ç« èhèV²³iç D×dçaöc³f oëèfbç
media production
facilities globally
$385m $385kv²
invested over the last AZá èfMY² amöK² o³ff³fçp v²hY²ç fïèÙb³f RcÅ èfècö³içM
decade to increase
capacity2A
GE HealthCare has a distinguished heritage of K²¿TÇ±ç« èhèV²³iç dÆå½ëèY² ôY² èRB ôpâZöK²³iç³f GK²
contrast AcÅcÅ cçh| èfèg²š ôhçV²çèkèT±öY² èfå½éXá dÆV²çör²³f
o¡ç³f, Aèg²cf dÅçöK²èRü Gfü èfèg²š K²cöoö¿TDZmöc³f
media development, o_ering a comprehensive
dÆV²çr² dÆaçc K²ö³f
product range across modalities, with a range of
concentrations and innovative packaging choices.
Long-Term Iodine Supply aéNá öh³içèa Açö³içèV²c o³ff³fçp
GE HealthCare investment: èRB ôpâZöK²³iç³f Bcög²«öh¿T±ý
From extraction to injection1 GuTDZÅçK²mc óZöK² BcöRK²mc
Extraction and Açö³içèV²c GåoTDZÅçK²mc I dÆöoèoü
processing of iodine
Production of API GèdAçB ódÆçV²çK²mc
Fill and finish ²èe²k I èe²ècm
Patient dose ô³fçMé³f ôV²çR
Increased costs2 fçèbáY² L³fP±
Iodine Açö³içèV²c
Energy GcçèRá
Freight dcÅ dè³ffpc
Labor ôkfç³f
Investment èfècö³içM
Despite increased costs, D×dçac L³fP± fïèÙb oôŠÃI, èRB ôpâZöK²³iç³f èc³fçda
GE HealthCare continues to K²¿TÇ±ç« èhèV²³iç o³ff³fçöp³f RcÅ èfècö³içM K²ö³f P±ököQ²
invest to secure iodinated
contrast media supply
GE HealthCare is èRB ôpâZ² ôK²³iç³f
securing and protecting aéNá-ôh³içèa Açö³içèV²c o³ff³fçp oëècèãP±Y² K²³föQ²
long-term iodine supply2
GE HealthCare Announces Multi-Year Agreement èRB pâZ ôK²³iç³f K²¿TÇ±ç« èhèV²³iç o³ff³fçöp³f RcÅ
with supplier to Secure Iodine Supply for Contrast o³ff³fpK²ç³féöa³f oõz fpë-fQ²³f èg²ŠK² Pë±èŠº K²³fç³f ôNçncç
K²ö³fôQ²
Media
Securing increased supply o³ff³fçôp³f v²hY²ç fç´V²çöcç I Rçdçôc Açö³içèV²c è³foçBèt²cü
capacity and increasing oëècèãPY²± K²ô³föQ²
iodine recycling in Japan
Long-term supplier èP±èk³f oõz aébá ôh³içèa o³ff³fçöp³f Pë±èŠº
agreement in Chile
Innovative Packaging Aèg²cf dÅçöK²èRü
+PLUSPAK™ 100% +dÈçodÅçK² 100%
è³foçBöK²k dÅçöK²èRü
recyclable packaging
Our +PLUSPAK packaging, used for contrast media K²¿TÇ±ç« èhèV²³iç³f RcÅ fÅfpç³f K²³fç Açhçöa³f
product, +dÈçodÅçK² dÅçöK²èRü 100 mY²çüm è³foçBöK²k K²³fç
içöf| kçBe²-oçBöK²k èfnökmc óZöK² Rçcç² iç³i ôi , Kÿ²çöP±³f
is 100% recyclable. A life-cycle analysis showed that
ôfçY²ök³f Yë²kcç³i Açhçöa³f dèkõdÆçdçBèkc ôfçY²k,59
our mY²çüm K²h dè³föfön³f v²èY² K²ö³f Gfü 45 mY²çüm K²h
polypropylene bottles, compared to glass, have a 59% GcçèRá L³fP± p³i| Açhçôa³f +dÈçodÅçK² ôfçY²ök ôoöK²—
lower environmental impact, and requires 45% less ²çè³f dÅçöK²èRü L³fPI± K²h Gfü K²h K²çfác Q²çd ôe²ök|
cumulative energy. Our +PLUSPAK bottles, also
require less
secondary packaging, helping reduce carbon
footprint.1
+PLUSPAK move towards a smarter choice +dÈçodÅçK² GLc åÄçTá± P±³io
Now available in GLc dçI³iç içöÎQ²
Flip-top cap
Omnipaque™
Administered since 1982, this low osmolar contrast
agent is indicated for intravenous, intra-arterial,
intrathecal, body cavity and oral use in
gastro-intestinal studies.1
Omnipaque has been unsurpassed by any
low-osmolar contrast media for either diagnostic
e_icacy or tolerability at equi-attenuating doses in
head-to-head trials.12-23
Bottle after bottle
Omnipaque’s +PLUSPAK
packaging support departmental efficiency
Colour coded labelling to prevent
administration errors
Important information to be is repeated
upside down so it’s easier to read at any angle
Reducing hazard and downtime with no
more broken bottles and injuries from the ring
pulls8
Reducing costs and environment impact
with less storage space and lower disposal
costs8-10
300
350
IMPORTANT INFO
IMPORTANT INFO
èeɲd-T±d K²Åçd
IoècdÅçèK²D
1982 óZöK² GB K²h Aoöhçkç³f K²¿TÇ±ç« GöR¿T±,
MÅçöåTDZç-Bö¿T±oèT±cçk d³fév²ç³i B¿TDZçög²cço,
B¿TDZç-AçèTá±³içk, B¿TDZçõZK²çk, fèV² K²Åçèg²èT± Gfü
hëL èaö³i fÅfpç³f pö³i P±ököQ²|
ô³fçM ècbáç³föc³f ôv²öŒ ôpV²-Të±-ôpV² TDZç³iök, AcÅ ôkç-
Ioöhçkç³f K²¿T±ç« èhèV²³iç, IhècdÅçK² ôK² K²çiáK²çè³fY²ç
fç opcmékY²ç³i A²Y²éŒºh K²³föY² dçö³fèc|
ôfçY²ök³f d³f ôfçY²k
IhècdÅçK² +dÈçodÅçK²
dÅçöK²èRü K²çiáK²çè³fY²ç oëècèãP±Y² K²ö³f
ôV²çôR³f hçd ôK² ècgëá²k ³fçLöY² K²çkç³f ôK²çV² ôköfèkü
Më³fµYòdíXá Y²ZÅ Id³f óZöK² ècôP±³f èaöK² ôaI³iç AçöQ²
içöY² ôi ôK²çc èaK² óZöK² d´V²ç iç³i
g²çzç ôfçY²k I K²Åçd óLçkç³f óZöK² AçNçôY²³f o¡çfcç K²h
p³i
ô«ç³f K²³föY² K²h Rç³iMç kçõM Gfü dè³fY²ÅçM K²³fç³f
L³fP± K²h I G³f óZöK² L³fP±± I dè³föfôn³f dÆg²çf K²h p³i
300
350
Më³fµYòdíXá Y²ZÅ
Më³fµYòdíXá Y²ZÅ
Patient after patient ô³fçMé³f d³f ô³fçMé
Omnipaque provides
IhècdÅçK² èfmÂçoôiçMÅY²ç I èft²d dÆaçc K²ö³f
reliabilty and choice

Indicated for intravenous, intra-arterial, body B¿TDZçög²cço, B¿TDZç-AçèTá±³içk, fèV² K²Åçèg²èT±,

B¿TDZçèZK²çk Gfü I³fçk fÅfpçö³f³f RcÅ
cavity, intrathecal and oral uses1
Approved for use in both adults and children1 dÆç› f³i©² I èmmëöa³f RcÅ AcëhèaY²
Scan after scan ©²Åçöc³f d³f ©²Åçc
Prescribing Aç¼ÄèfmÂçôo³f oçõZ IhècdÅçK² ódÆ区çBf K²³fç iç³i
confidence with
Omnipaque
In a prospective, randomized study of 8,931 CT 8931 èoèT± ô³fçMéöa³f ècö³i GK²èT± o¡çfÅ ³fçö—²çhçBRV²
ohév²ç³i ôaLç óMöQ² AcÅ ôK²çc GkIèoGh Yë²kcç³i
patients, no LOCM was better tolerated than
IhècdÅçöK²³f opcmékY²ç AöcK² g²çk
Omnipaque3
Taste after taste oÂçöa³f d³f oÂça
Enhancing oral hëõL³f dÆèoèV²³iô³f³f Aèg²…²Y²ç g²çk K²ö³f
procedures
81% of adult body CT 81% dÆç› f³i©² ô³fçMé içôa³f èoèT± pöf Y²ç³fç
patients who expressed ad V²ç³iTDZçBöiçö³iT± G³f Yë²kcç³i IdècdÅçK² dQ²¿a K²ö³f
preference preferred
Omnipaque over diatrizoate5
98% of pediatric patients èoèT± pöf Ghc 98% èmmë ô³fçMé, AöcöK²³f f³io 5 G³f K²h
undergoing abdominal CT IhècdÅçöK²³f ècèa᧠dè³fhçc óLö³iöQ²c|
many of whom were under 5,
drank the required volume of
Omnipaque6
Visipaque™ èg²èodÅçK²
Visipaque is an isomolar contrast agent K²¿TÇ±ç« GöRö¿T±³f T±K²èoèT± ódÆçe²çBk DšY² K²³fç³f
developed to further improve the toxicity RcÅ dÆå½ëY² K²³fç pö³iöQ² èg²èodÅçK², GK²èT±
AçBöoçöhçkç³f K²¿TÇ±ç« GöR¿T| ôi o³f ô³fçMéöa³f
profile of contrast agents, suitable for
K²çèVá²ö³içg²ç©ë²kç³f Gfü èK²V²èc³f ohoÅç AçöQ² Y²çöa³f
patients considered at high risk RcŠDdi늺|
for cardiovascular or renal
insult.1,2,3
Enhancing dÆèoèV²³iö³f³f Aèg²…²Y²ç DšY² K²³fç
PROCEDURAL
COMFORT1
Reduced patient ô³fçMé³f Aoëèfbç K²h p³i
Discomfort
Less patient ô³fçMé ôK² K²h c´V²çP±´V²ç K²³föY² p³i
Movement
Lower K²h K²¿TDZçö«³f dÆö³içRc p³i
contrast use
Fewer repeat dëc³fç³i d³fév²ç K²h K²³föY² p³i
Studies
Pain was lower with iodixanol than with LOCM* GkIèoGh-G³f Yë²kcç³i Açö³içèV²uçck-G fÅçZç K²h p³i
(n=8,087)1 (Gc=8087)
Visipaque HELPS to maintain èg²èodÅçK², ô³fçMé ôK² Aç³fçh dÆaçc K²ö³f
PATIENT COMFORT
Reduce patient discomfort ô³fçMé³f ohoÅç K²h K²ö³f
Increased patient ô³fçMé³f² Aç³fçh óZöK² oçèfáK² e²kçe²k g²çk p³i
comfort can help
improve throughput
Patient comfort is important in busy interventional B¿T±ç³fög²cmcçk ô³fèV²IkèR dÆ茺³iç³i ô³fçMé³f Aç³fçh
AöcK² Më³fµYòdíXá| M³fh/fÅçZç³f Acëgë²èY² õZöK²
radiology suites. Sensation of heat/pain may lead to
ô³fçMé cô´V² ôiöY² dçö³fc, Q²èf³f hçc Lç³fçd pöY² dçö³f Gfü
patient movement, poor image quality and repeat dëc³fç³i d³fév²ç³f dÆö³içRc pöY² dçö³f I L³fP± fç´V²öY² dçö³f|
examinations creating increased radiation and ²
costs27,28
Visipaque has been shown to significantly reduce GkIèoGh29-33 G³f Yë²kcç³i èg²èodÅçK²-G, AoÂçèå½,
M³fh/fÅçZç³f Acëgë²èY² K²h p³i|G³f óZöK² K²çèVá²³içK² I
discomfort, heat and/or pain compared to LOCM29-33
èK²V²èc³f ohoÅç K²h p³i|
as well as reducing the risk of major cardiac and
renal events.
Visipaque: Prepared for èg²èodÅçK²-DÎP± Sëÿ±èK²díXá ô³fçMé³f RcÅ dÆå½ëY²
HIGH RISK PATIENTS
Appropriate selection of DÎP± Sëÿ±èK²díXá ô³fçMé³f ôv²öŒ ô³fçM ècbáç³fc I
B¿T±ç³fög²cmcçk dÆèoèV²³i³f BöhèRü-G iZçiZ K²¿TDZç«
contrast media for
èhèV²³iç èföfP±cç K²³fç DèP±Y² içöY² dÆèY²Kí²k
necessary diagnostic or dè³fèå¾èY² ôhçK²çèfkç K²³fç o¡f p³i|
interventional procedure
imaging in high risk
patients should be
considered to help mitigate
the risk of adverse events.9
Visipaque, an iodinated GB of èföfP±cç K²ö³f B¿TDZç-Aç³fèT±³içk I B¿TDZçög²cço
dÆèoèV²³iö³f³f RcÅ èg²èodÅçK², Açö³içèV²c i늺 AçBöoç-
iso-osmolar, isotonic
Aoöhçkç³f, AçBöoçT±ècK² K²¿TÇ±ç« GöR¿T±, dÆå½ëY²
contrast agent indicated K²³fç pö³iöQ²|
for multiple intra-arterial
and intravenous
procedures was prepared
with this in mind.3
Features øfèm¨Å
Your choice of iodinated contrast Açö³içèV²c i늺 K²¿TÇ±ç« èhèV²³iç ècbáç³föc³f dÆèY²Kí²k
media could help mitigate dè³fèå¾èY²³f öhçK²çèfkç K²³föY² oçpçiÅ K²³föf
adverse events

Interventional, structural, or endovascular procedures B¿T±ç³fög²cmcçk, åTDZçK²P±ç³fçk fç Gö—²çg²çoKë²kç³f

dÆèoèV²³i³f (ôihc èT±Gèg²AçB, èoèT±I, èdèo)-G ôfèm
(e.g., TAVI, CTO, PC) may need to use higher volumes of
hçŒç³f Açö³içèV²c i늺 èoGh dÆö³içRc pôY² dçö³f| G³f
iodinated CM, reducing the frequency of adverse óZöK² dÆèY²Kí²k Afå¾ç³f o¡çfcç K²h p³i| Y²çB dÆZh èac
reactions has therefore been a driving force in the óZöK²B GBèT± ô³fçM ècbáç³föc³f RcÅ Lëf fÅfpïY²|
development of these diagnostic agents since their
initial introduction.9,10
Oncology AcöK²çkèR
With cancer patients K²ÅçÛoç³f ô³fçMéöa³f oõz dÆèY² bçõd
every step of the way
Contrast enhanced CI is important to every step of K²Åç²Ûoç³f ô³fçMéöa³f ô³fçM ècbáç³fc I dÆèY² bçõd
hècT±è³fü Gfü e²ökçAçõd K²¿TÇ±ç« i늺 èoAçB Lëf
a cancer patient’s journey from diagnosis and
Më³fµYòdíXá|
staging to monitoring and follow-up.34
Cancer patients may be susceptible to the adverse K²ÅçÛoç³f ô³fçMéöa³f Açö³içèV²c i늺 èoGh óZöK²
èK²V²èc³f dÆg²çf d´V²öY² dçö³f | Y²çöa³f AöcK² èoèT±
renal effects of iodinated CM as they are exposed
©²Åçöc³f dÆö³içRc p³i|
to multiple nephrotoxic insults, predisposed to
dehydration and require many CT scans.34-36
• CI-AKI and CKD are highly prevalent.37 èoAçB-GöK²AçB Gfü èoöK²èV² AY²ÅÛ½ dÆP±èkY²
Visipaque can help cancer patients by èg²èodÅçK² K²Ûoç³f ô³fçMéöa³f oçpçiÅ K²³föY² dçö³f
Delivering diagnostic accuracy through èK²V²èc ohoÅç i늺 ô³fçMéöa³f K²¿TÇ±ç« i늺 èoèT±³f
oçpçöiÅ ô³fçM ècbáç³fc oèU±K²Y²ç Göc ôa³i|
enabling valuable contrast-enhanced CT in
patients with renal impairment38
Addressing renal complications considering èK²V²èc ohoÅç op DP±P± Sëÿ±èK²díXá ô³fçMéöa³f
RèT±kY²ç ôhçK²çèfkç K²³fç
vulnerable patients with multiple risk factors38-40
Minimising contrast associated pain protecting K²¿TÇ±ç« RècY² fÅçZç I AoÂèå½ K²h K²³fç
patient comfort and care41-42
Clariscan™ t²Åçè³f²©²Åçc
Clariscan™ (gadoteric acid) is macrocyclic t²Åçè³f©²Åçc (MÅçöV²çöT±è³fK² GèoV²), hÅçöŒºçoçBèt²K²
gadolinium-based contrast agent expertly MÅçöV²çèk³içh i늺 K²¿TÇ±ç« GöR¿T±, èRB ôpâZöK²³iç³f
Ùfç³fç ècèháY²| GèT± GhAç³fAçB dÆèoèV²³iö³f g²çk e²k
manufactured by GE HealthCare used to
ódöY² oçpçiÅ K²ö³f
enhance visualization in MRI procedures
across a range of indications.
Clariscan is a macrocyclic, t²Åçè³f©²Åçc hÅçöŒºçoçBèt²K² èRèfèoG| dÆZh èac óZöK²
general-purpose GBCA. Used to oç³fç èföm 17 èhèk³iôc³f ôfèm GhAç³fAçB dÆèoèV²³i³f
²K²³föY² oçpçiÅ K²ö³föQ²|èR B ôpâZ ôK²³iç³f dÆå½ëY²
enhance over 17 million MRI
t²Åçè³f©²Åçc èfèg²š dÅçöK²èRü-G dçI³iç iç³i Gfü G³f
procedures globally since launch T±kçö³fèfèkèT± dÆe²çBk dÆèY²è¨Y²|
Clariscan is manufactured in-house
by GE HealthCare in a range of
packaging options and has a
well-established tolerability profile.3
At a glance GK² cRö³f
Macrocyclic hÅçöŒºçoçBèK²èkK² MU±c
structure
Macrocyclic, ionic chelate hÅçöŒºçoçBèK²èkK², Açö³içècK², pçB K²çöcèT±K² I
ZçöháçV²çBcçèoK² ô«èfèkèT±
provides high kinetic and
themodynamic stability1
Expertly èfömn‚g²çöf dÆå½ëY²
manufactured
Quality manufacture and MëcMY² hçc oàdš dÆå½ëèY²K²³fc Gfü èRB K²Yï²K²
delivery expertly managed ôV²èkg²çè³f K²ö¿TDZçk
by GE for greatest control
Established dÆèY²è¨Y² T±kçö³fèfèkèT±
tolerability
Over 17 million patient 17 èhèk³iöc³f ôfèm ô³fçMé ôK² ôaI³iç pö³iöQ²
administrations with low
level of adverse events2,3
Convenient oëèfbçRcK² dÅçöK²èRü-³f èfK²¤
packaging options
Vials, prefilled syringes and G²g²ç³içk, èdÆèe²âV² èoè³f…² Gfü +dÈçodÅçK² ôfçY²k,
+PLUSPAK bottles in a range èfèg²š g²èkDöh
of volumes
Structure
Gadoteric acid: MU±c
the only macrocylic, ionic molecule hÅçöŒºçoçBèt²K², Açö³içècK² hèkèK²Dk
Stability refers to how tightly the ô«èfèkèT± pk K²Y² mŠº K²ö³f MÅçöV²çèkèc³içh Aç³ic
hèkèK²Dk ôK² bö³f ³fçõL Gfü Q²ö´V² içI³iç³f o¡çfcç
gadolinium ion is bound to the chelating
molecule and how likely it is to dissociate.
Gadoteric acid is the only macrocyclic, MÅçöV²çöT±è³fK² GèoV² hÅçöŒºçoçBèt²K², Açö³içècK²
hèkèK²Dk of MÅçöV²çèkèc³içh i늺 K²¿TDZçö«
ionic molecule across all
gadolinium-based contrast agents.
In-vitro data suggest that combining a Bc-èg²öTDZç V²çT±ç óZöK² Rçcç iç³i ôi MÅçöV²çèkèc³içh
èV²èoèoô³imôc³f Sëÿ±èK² K²h K²³föY², DÎP± K²çBöcèT±K²
macrocyclic structure for high kinetic
ô«èfèkèT± op ZçöháçV²ç³icçèhK² ô«èfèkèT³f Rc³i
stability with ionicity for thermodynamic ±hÅçöŒºçoçBèt²K² MU±c GK²Œ K²³fç ôiöY² dçö³f
stability, may help to reduce the potential
risk of gadolinium dissociation.1
Usage
A broad range of indications and
well-established tolerability profile3
Clariscan is indicated for diagnostic contrast
enhancement in:3
MRI of the CNS including the brain, spine and
surrounding tissue
Whole body MRI including the major organs pelvis,
breast and muscoskeletal system (not recommended
for children below 6 months)
MR angiography including lesions or stenoses of the
non-coronary arteries (adults only)
Clariscan should be used when diagnostic
information is essential and not available with
unenhanced magnetic resonance imaging (MRI).
Trust the Ability of Clariscan
and OPT for it Today!
Commitment
Keeping production for Clariscan
in-house so you can be
assured standards are
maintained from start
to finish
GE HealthCare has invested
over $385M since 2013 in
expansion of our
manufacturing capacity to
fÅfpç³f
fÆV² ô³f…² BcèV²öK²mc Gfü dÆèY²è¨Y² T±kçö³fèfèkèT±
ódÆçe²çBk
V²ç³iMcè«K² K²¿TÇ±ç« DšY² K²³föY² t²Åçè³f©²Åçc oçpçiÅ
K²ö³f
èoGcGo, ôfÆc, ådçBc I dçmÂá èT±oë³f GhAç³fAçB
dëö³fç m³féö³f³f GhAç³fAçB, ôhR³f A³fMçc ódkèg²o, fv² Gfü
hçö©²çö©²èkT±çk èoö«h op (6hçöo³f K²h f³iöo³f èmmëöa³f
RcÅ cöp)
GhAç³f GcèRIMÆçèe² , ôkpoc fç ôoöT±öcçöoo cc-K²³fcçè³f
Aç³fT±çè³f op( dÆç›-f³i©²öa³f Rc¯)
²t²Åçè³f©²Åçc fÅfpç³f mëbë hçŒ ô³fçM ècbáç³föc³f RcÅ
Ddi늺 Gfü hÅçMöcèT±K² ô³föoçcÅçÛo
BöhèRü(GhAç³fAçB) ôY² dçI³iç iç³icç
t²çè³f©²Åçöc³f v²hY²ç³f Id³f g²³foç K²³fµc Gfü AçRB ôföQ²
ècc
AzéK²ç³f
t²çè³f©²Åçöc³f Bc-pçDo dÆV²çK²mc P±çèkö³i içI³iç³i
oëècèãP±Y K²ö³f
më³fµ óZöK² ômn diáÛ½ Mëchçc fRç³i ³fçLç
èRB ôpâZöK²³iç³f 385 èhèc³ic V²kç³f èfècö³içM K²ö³föQ²,
ècöRôa³f hÅçcëe²ÅçÊP±çè³fü v²hY²ç fç´V²çöcç³f RcÅ içöY²
K²¿TÇ±ç« GöRö¿T±³f P±çèpaç ôhT±çöcç iç³i|
meet growing demand for
our contrast agents.
All our manufacturing sites Açhçöa³f ofK²èT± hÅçcëe²ÅçÊP±çè³fü èoèRGhèd oÂéKï²Y²|
Açh³fç oç³fç èföm³f èc³ihK² GöRèÛo³f oõz èhökèhöm K²çR
are cGMP-accredited and we
K²è³f, AèfèÎQ²š o³ff³fçp P±çèkö³i ôiöY²|
work closely with regulatory
agencies globally to
ensure quality supply.7
Omniscan™ Ihèc©²Åçc
To protect patients from the ô³fçMé³f o¡çfÅ pçBdç³fôocèoèT±èg²èT± èf茺³iç³f Sëÿ±èK²
Potential risk of immediate óZöK² ècdça ³fçLöY²
hypersensitivity reactions
Lower rate of acute adverse reactions than other AcÅ èRèfèoG óZöK² dÆèY²Kí²k èf茺³iç³f o¡çfcç K²h
GBCAs in its class1
Omniscan had the èfèg²š èRèfèoG Yë²kcç³i Ihèc©²Åçöc GkçèRá K²h p³i
lowest allergic reaction
rate across the entire
GBCA class1
A meta-analysis of nine studies in which immediate 716978 dÆö³içõM èRèfèoG-³f Y²ç×v²cçY² èf茺³iç³f c³ièT±
Möfncç³f ôhT±ç-Gcçèkèoo K²³fç pö³iöQ²
reactions to GBCAs were recorded from a total of
716,978 administrations was conducted1
Subclass oçft²ço
GBCA èRèfèoG
Rate [95% CI] of allergic-like reactions AÅçkçèRá³f hY²c èf茺³iç (95 mY²çüm èoAçB) ô³fT± K²³fç
Linear non-ionic èkèc³iç³f cc-Açö³içècK²
Linear ionic èkèc³iç³f Açö³içècK²
èkèc³iç³f Açö³içècK²
Linear ionic
èkèc³iç³f Açö³içècK²
Linear ionic èkèc³iç³f Açö³içècK²
Linear ionic hÅçöŒºçoçBèt²K² cc-Açö³içècK²
Macrocyclic non-ionic hÅçöŒºçoçBèt²K² cc-Açö³içècK²
hÅçöŒºçoçBèt²K² Açö³içècK²
Macrocyclic non-ionic
Macrocyclic ionic
OMNISCAN Ihèc©²Åçc
Magnevist® hÅçMöcèg²«
dÆçBöhçèg²«
Primovist®
hçèâT±pÅçÛo
MultiHance® g²Åçöoçèg²«
Vasovist® MÅçöV²çèg²«
Gadovist® ódÆçpÅçÛo
ProHance® ôV²çT±çö³fh
Dotarem®
Adapted from Behzadi1 ôfpRçèa óZöK² MïèpY²
Log total reaction rate per 10,000 injections dÆèY² 10000 BcöRK²möc èf茺³iç³f pç³f
1, 10, 100 1,10,100
Low frequency of Ihèc©²çöc pçBdç³föoèÛoèT±èg²èT± èf茺³³iç K²h ôaLöY²
immediate dçI³iç óMöQ²
hypersensitivity
reactions reported
with Omniscan2
All immediate GBCA hypersensitivity reactions MY² 6 fQ²ö³f pçodçY²çök èRèfèoG pçBdç³föocèoèT±èg²èT±
èf茺³iç³f of NT±cç è³fèg²D K²³fç pö³iöQ²|
spontaneously reported at the hospital in the
6 years were reviewed2
Frequency of immediate hypersensitivity Y²ç×v²cçY² pçBdç³föocèoèT±èg²èT± èf茺³iç³f
reactions (% of patients) èeƲK²ö³ièÛo(mY²K²³fç ô³fçMé)²
0.25 0.25
0.20 0.2
0.15
0.15
0.10 0.1
0.05 0.05
0
0
0.220 0.220
MultiHance® hçèâT±pÅçÛo
Gc=706
n=6,361
èkèc³iç³f Açö³içècK²
linear ionic
0.116 0.116
Primovist® dÆçBöhçèg²«
Gc=5152
n=5,152
èkèc³iç³f Açö³içècK²
linear ionic ²

0.099 0.1099
Gadovist® óMçöV²çèg²«
Gc=33,242
n=33,242
hÅçöŒºçoçBèt²K²
macrocyclic
0.080 0.080
Dotarem® ôV²çT±çö³fh
Gc=38580
n=38,580
hÅçöŒºçoçBèt²K²
macrocyclic
0.061 0.061
Magnevist® hÅçMöcèg²«
Gc=42323
n=42,323
èkèc³iç³f Açö³içècK²
linear ionic
0.013 0.013
Omniscan Ihèc©²Åçc
Gc=15959
n=15,959
linear non-ionic èkèc³iç³f cc-Açö³içècK²

Low incidence of K²çèVá²ö³içg²ç©ë²kç³f GhAç³f ôoèT±ü-G Y²éfÆ dÆèY²Kí²k

acute adverse èf茺³iç³f K²h o¡çfcç
reactions in the
cardiovascular MR
setting3
Prospectively surveyed in 57 European centres3 o¡çfÅg²çöf 57 Bö³fçõd³f ôK²ö¿aÆ ohév²ç K²³fç pö³iöQ²
Acute adverse reactions (% of patients) Y²éfÆ dÆèY²Kí²k èf茺³iç³(mY²K²³fç ô³fçMé³f)
0.5 0.5
0.4 0.4
0.3
0.3
0.2
0.2 0.1
0.1 0
0
0.42 0.42
MultiHance® hçèâT±pÅçÛo
Gc=706
n=706
èkèc³iç³f Açö³içècK²
linear ionic
0.19 0.19
ProHance® ódÆçpÅçÛo
Gc=1,045
n=1,045
hÅçöŒºçoçBèt²K²
macrocyclic
0.16 0.16
Magnevist® hÅçMöcèg²«
Gc=12,810
n=12,810
èkèc³iç³f Açö³içècK²
linear ionic
0.12 0.12
Dotarem® ôV²çT±çö³fh
Gc=4,235
n=4,235
hÅçöŒºçoçBèt²K²
macrocyclic
0.10 0.10
Gadovist® óMçöV²çèg²«
Gc=9,378
n=9,378
hÅçöŒºçoçBèt²K²
macrocyclic
0.05 0.12
Omniscan Ihèc©²Åçc
Gc=6,116
n=6,116
èkèc³iç³f cc-Açö³içècK²
linear non-ionic
Adapted from Bruder2 fƵV²ç³f óZöK² Aèg²öiçèRY²
The GBCA investigated are not all licensed for K²³fcçè³f AçTá±çè³f³f ô³fçM dè³fv²ç K²³fç³f RcÅ èRèfèoG
d³fév²ç oÂéKï²Y² c³i
coronary artery disease investigations
Low frequency of Ihèc©²çöc pçBdç³föoèÛoèT±èg²èT± èf茺³iç³f ôaLöY² dçI³iç
immediate óMöQ²
hypersensitivity
reactions reported
with Omniscan4
Suitable for most patients and indicated for most of b³föc³f ô³fçMé I dÆç³i of èoBGhAç³f dÆ茺³iç³f RcÅ
Ddi늺
CEMR procedures4
Indication kv²c
Adult dÆç› f³i©²
Pediatric èmmë
(above 2 years) (2 fQ²ö³f³f ôfèm)
Standard oçbç³fc ôV²çR
Dosage*
CNS (Central Nervous System) èoGcGo(ôo¿TDZçk cçgá²ço èoö«h)
Brain ôfÆc
0.1 mmol/kg IV 0.1 Ghöhçk /ôK²èR IV
Spine ådçBc
0.1 mmol/kg IV 0.1 Ghöhçk /ôK²èR IV
Body m³fé³f
Kidney K²V²èc
0.1 mmol/kg IV 0.1 Ghöhçk /ôK²èR IV
Intrathoracic B¿TDZçõZç³fçBK²
0.1 mmol/kg IV 0.1Ghöhçk /ôK²èR IV
Intra-abdominal B¿TDZç-GföV²çèhcçk
0.1 mmol/kg IV 0.1 Ghöhçk /ôK²èR IV
Pelvic ódkèg²K²
0.1 mmol/kg IV 0.1 Ghöhçk /ôK²èR IV
Proven GBCA suitable for the ôfèm³fg²çM ô³fçMé içöa³f K²¿TÇ±ç« i늺 GhAç³fAçB pöÎQ²
majority of patients undergoing Y²çöa³f ôv²öŒ èRèfèoG Ddi늺
contrast-enhanced MRI5
Suitable for rapid ³fçèdV² ôfçkço dÆèoèV²³iö³f³f RcÅ Ddi늺
bolus procedures5
Minimal patient ô³fçMé³f AoÂèå¾ K²h p³i
discomfort6
Low risk of adverse dÆèY²Kí²k èf茺³iç³f Sëÿ±èK² K²h
reactions6
Approved for use in a broad Bè—²öK²möc³f èfå½ïY² ô³fõ…²³f RcÅ AcëhèaY²
range of indications7
Trusted for more than 2 amöK²³f ôfèm ohö³i èfmÂå½
2 decades8
We deliver clinical Açh³fç Adçö³fmcç³f ômƨöYò³f dÆèY² Açhçöa³f
excellence through our AzéK²çô³f³f hçbÅöh èt²ècK²çk ômƨYò dÆaçc K²³fèQ²
commitment to
operational excellence
Our expansion in manufacturing capacity D×dçac v²hY²ç fïèÙb³f hçbÅöh Açh³fç P±çèpaç dí³fõX
AèfèÎQ²š o³ff³fçp oëècèãP±Y² K²è³f|
ensures continuous supply to meet
your demand.9
Our multiple local distribution centers èfèg²š å¾çöc Açhçöa³f èV²èåTDZèfDmc ôo¿T±ç³f Açdcç³f
o³ff³fçp oëècèãP±Y² K²ö³f içöY² Açdèc dÆèoèV²³i³f P±çèkö³i
allow you to schedule procedures
ôiöY² dçö³fc
with confidence.
Our cGMP accredited sites provide èoèRGhèd oÂéKï²Y² oçBT± dÆV²çr² I dÆöoöo³f Mëchçc
oëècèãP±Y² K²ö³f
confidence in product and process
quality.10
01 01
02 02
03
03
TechAspire™ ôT±K²Gådç³iç³f
Online Learning Platform AckçBc kç³fècü dÈçT±e²há
GE HealthCare introduces TechAspire™, an online èRB ôpâZöK²³iç³f ècö³i GöoöQ² ôT±K²Gådç³iç³f, GK²èT±
educational initiative to meet the educational and AckçBc èmv²ç³f DöaÅçM| GLçöc ôT±K²öcçkèR« èmv²ç
ARác K²ö³f ècöRöa³f av²Y²ç fç´V²çöY² dç³föfc|
developmental needs of technologists
TechAspire™ provides technologists an opportunity ôT±K²Gådç³iç³f, ôT±K²öcçkèR«ôa³f oëöiçM ôa³i ècöRöK² I
of self improvement and career development. ècöR³f ôK²è³f³iç³f ôK² DšY² K²³fç³f| AèV²ö³iç èg²èŠK² GB
Bkçècáü dÈçT±e²öhá AckçBc d³fév²ç³f I oëèfbç AçöQ²|
This e-learning resource offers audio based learning
with interactive assessments.
Interactive B¿T±ç³fGèr²g² hçèâT±èhèV²³iç ôK²çoá
multimedia courses
Easy to login kMBc K²³fç opR
User-friendly opR fÅfpç³föiçMÅ
Easy to navigate cÅçèg²õMT± K²³fç opR
Learn at your own free pace ècöR³f MèY²öY² ômLç
Salient Features: dÆbçc øfèm¨Å
Similar to instructor-led Açok t²ço³fµöh³f hY²c g²çPëá±³içk t²ço
virtual classroom
sessions
Online assessments AckçBc AÅçöooöh¿T±
Accessible 24 X 7 fÅfpç³föiçMÅ
Users can re-visit ôi ôK²çc ôoK²möc dëc³fç³i içI³iç iç³i
any section
Take advantage of the learning portal to GB kç³fècü ódçTá±çök³f oëèfbç ècc Gfü ôhèV²öK²k I ô³fçM
keep abreast of medical and diagnostic ècbáç³fc dÆèoèV²³iö³f dÆMèY² I èfK²çöm³f èfnö³i Rçcëc
Gfü ècöR³f av²Y²ç fïèÙb K²³fµc|
developments and upgrade your skills
and knowledge.
TechAspire Website öT±K²Gådç³iç³f Iö³ifoçBT±
Online Courses & Modules AckçBc dçU±Œºh I hèV²Dk
Section I èfg²çM 1
Basics of Contrast Media K²¿TÇ±ç« èhèV²³iç ôhûèkK²
• Introduction of Contrast  K²¿TDZö«³f gë²èhK²ç
• Toxicities of Contrast Media  K²¿TÇ±ç« èhèV²³iç³f T±èuèT±
 K²¿TÇ±ç« èhèV²³iç³f opcmékY²ç
• Tolerability of Contrast Media
 èc³fçdŠç³f èföfP±cç Gfü dÆèY²Kí²k dè³fèå¾èY²³f
• Safety consideration and Management of ôhçK²çèfkç
Adverse Reactions  MÅçöV²çèkèc³içh i늺 K²¿TÇ±ç« GöR¿T±
• Gadolinium based contrast agents
Section II èfg²çM 2
Basics of Radiology ô³fèV²³ikèR³f ôhûèkK²
• Basics of Computed Tomography  K²hèdDöT±V² ôT±çöhçMÆçèe² ôhûèkK²
• Basics of MRI Physics, Anatomy &  GhAç³fAçB èe²èou, GcçT±èh Gfü èoK²ö³iöÛo
ôhûèkK² ²
Sequences  K²¿TDZçö«³f ôhûèkK²
• Basics of Contrast  K²¿TÇ±ç« i늺 èoèT±-³f dÆö³içM
• Applications of contrast Enhanced CT  K²¿TDZ« i늺 GhAç³fAçB-³f dÆö³içM
• Applications of contrast enhanced MRI
Section III èfg²çM 3
Basics of Cardiac K²çèVá²³içK² K²ÅçõZ³fçBöRmc ôhûèkK²
Catheterisation
• The Anatomy & Physiology of the Human  K²çèVá²Ig²çoKë²kç³f èoö«öh³f AÅçcçT±èh I
Cardiovascular System èe²èRIkèR
 ³föŠº³f èm³fç d³fév²ç³f Q²èf ôcIiç³f dÙbèY²
• Imaging technique for screening of blood  K²çèVá²³içK² K²ÅçZ kÅçöf ôT±K²ècèm³içöc³f
vessels gë²èhK²ç
• Role of a Technician in a cardiac cath lab  K²çèVá²³içK² K²ÅçZ kÅçöf ô³fèV²ö³imc óZöK²
• Radiation safety in a Cardiac Cath Lab oë³fv²ç
 K²çèVá²³içK² K²ÅçZ kÅçöf K²¿TÇ±ç« èhèR³iç
• Utilisation of contrast media in cardiac fÅçfpç³f
catheterisation laboratory
Section IV èfg²çM 4
Basics of Anatomy AÅçcçT±èh ôhûèkK²
• Respiratory System & function overview  mÂçoiÛ» I Y²ç³f K²çR
• The Circulatory System  oüfpcY²Û»
 åÀç³iëY²Û»
• The Nervous System
 hçcf m³féö³f³f MU±c
• Organisation of Human Body  K²x²çkY²Û»
• The Skeletal System
Visit ôaLëc
www.TechAspire.com www.TechAspire.com
for latest updates and courses ômn AçdöV²T± I dçU±ÅŒºöh³f RcÅ
Certificate of Completion oàdíXá K²³fç³f d³f oçèTá±èe²öK²T±
GE HealthCare Certifies that èRB ôpâZ ôK²³iç³f oçèTá±e²çB K²³föQ² ôi
has Successfully Completed TechAspire Online K²¿TÇ±ç« èhèV²³iç ôhûèkK² Id³f öT±K²Gådç³iç³f AckçBc
Learning Course on kç³fècü dçU±ÅŒºh oe²k g²çöf oàdíXá K²ö³föQ²c
Basics of Contrast Media
On GB Y²çè³fõL
Certificate of Completion oàdíXá K²³fç³f d³f oçèTá±èe²öK²T±
GE HealthCare introduces an online ±èRB ôpâZöK²³iç³f ècö³i GöoöQ²c AckçBc kç³fècü dÈçT±e²há
learning platform for Radiologists ô³fèV²ö³içkèR« Gfü ô³fèV²IkèR³f Q²çŒöa³f RcÅ
and Radiology Students.
RadAspire ³fÅçV²Gådç³iç³f
An online learning ô³fèV²IkèR ódmç³i i늺 fÅ芺öa³f RcÅ AckçBc kç³fècü
dÈçT±e²há
platform for Radiology
Professionals
RadAspire is an e-learning resource which provides fÅçV²Gådç³iç³f GK²èT± B-kç³fècü dÈçT±e²há iç ô³fèV²IkèR«
radiologists I ô³fèV²IkèR³f Q²çŒöa³f ôK²è³f³iç³f DšY² K²³fç³f oëöiçM ôa³i
and radiology students with an opportunity for
professional
development.
RadAspire offers not just interactive eModules with fÅçV²Gådç³iç³f-G Kë²BR, AèV²I-èg²èV²I ódÆçÆMÆçh op
quizzes, B¿T±ç³fGèr²g² BhèV²Dôk³f dçmçdçèm èfèm¨Å ô³fèV²IkèR³f
fÅ芺öa³f B-ôkK²P±ç³f I dçI³iç iç³i| GLçöc AöcK² ô³fèV²IkèR
audio and video-based learning programs, but also
Iö³ièfcç³f Açö³içRc K²³fç p³i| RçY²é³i I AçÛ½RáçèY²K²
offers ô³fçèV²IkèR fŠºçôa³f fŠºïY²ç I ôK²o «çèV² GB hèV²Dök
e-Lecture Series by esteemed Radiology KOLs. It dçI³iç iç³i|
also hosts a
number of Radiology Webinars led by National &
International
Radiology Speakers and case studies by
distinguished
Radiology Professionals.
These interactive multimedia courses will allow you to Açdèc Açdcç³f MèY²öY² GB B¿T±ç³fGèr²g² hçèâT±èhèV²³iç
learn at dçU±ÅŒºöh èmLöY² dç³föfc| GèT± opR fÅfpç³föiçMÅ Gfü
kM-Bc I cÅçèg²õMT± K²³fç opR|
your own pace.
It is user-friendly, easy to login and easy to navigate.
www.radaspire.com www.radaspire.com
Salient Features dÆbçc øfèm¨Å
Similar to Instructorled Açok t²ço³fµöh³f hY²c g²ç³fPë±³içk t²ço
virtual classroom
sessions
Access to digital èV²èRT±çk kçBöfÆè³f³f oëèfbç
library of references
Assignments/Online AÅçoçBcöh¿T±/AckçBc d³fév²ç
assessments
Accessible 24 X 7 24 X 7 DdkÞb
e-Lecture Series by oàhçècY² fÅŠºçöa³f oõz B-ôkK²P±ç³f
Esteemed Speakers
Webinar Series by RçY²é³i I AçÛ½RáçèY²K² fŠºçöa³f oõz Ièfcç³f
National and
International Speakers
RadAspire Website Login Details èK² g²çöf ³fçV²Gådç³iç³f Iö³ifoçBöT± kMBc K²³föfc
Here is how to register for RadAspire online: AckçBc èK² GB g²çöf ³fçV²Gådç³iç³f-G ô³fèR«ç³f K²³föfc
Go to http://www.radaspire.com http://www.radaspire.com -G içc
01 01
02 02
03
03
04
04 05
05 06
06
Login or Register kMBc fç ô³fRçB«ç³f
Go to Register ô³fèR«ç³f-G içc
Webinars Iö³ièfcç³f
E-Lectures B-ôkK²P±ç³f
Accessing your e-learning B-kç³fècü G içc
Certificate oçèTá±èe²öK²T±
Visit www.radaspire.com - Take advantage of this www.radaspire.com èg²èRT± K²³fµc| GB kç³fècü
learning portal to keep abreast of medical and ódçTá±çök³f oëèfbç ècc Gfü ôhèV²öK²k I ô³fçM ècbáç³fc
diagnostic procedural developments and upgrade your dÆ茺³iç³i dÆMèY² I èfK²çöm³f èfnö³i Rçcëc Gfü ècöR³f
av²Y²ç fïèÙb K²³fµc|
skills and knowledge.
© 2023 General Electric Company. All rights reserved. 2023 ôRcçö³fk BökèrDzK² ôK²çàdçèc| of oŠç oë³fèv²Y²| èR
GE and GE Monogram are registered trademarks of Gfü èR ôhçöcçMÆçh ôRcçö³fk BökèrDzK² ôK²çàdçèc³f
ècf虲Y² ôTDZV²hçKá²| èRB ôpâZôK²iç³f, ôRcçö³fk
General Electric Company.
BökèrDzK² ôK²çàdçèc³f mçLç|
GE HealthCare, a division of General Electric
Company.
Wipro GE HealthCare Private Limited DBõdÆç èRB ôpâZöK²³iç³f dÆçBög²T± èkèhöT±V²
www.gehealthcare.in www.gehealthcare.in
JB01787IN/Sep/2023 JB01787IN/Sep/2023